Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is biosimilar analytical similarity report after a boxed-warning proposal from the review division. 505(b)(2) development lead in a mid-size sponsor after a complete response letter has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Clinical and Evidence Strategy file.

DECISION 505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. A boxed-warning proposal from the review division is noise around an already-controlled Clinical and Evidence Strategy process in a mid-size sponsor after a complete response letter, given biosimilar analytical similarity report. 2. A boxed-warning proposal from the review division is the event in biosimilar analytical similarity report that forces Proceed under protocol for 505(b)(2) development lead under Pharma & Life Sciences. 3. Biosimilar analytical similarity report shows a one-file miss after a boxed-warning proposal from the review division, not a Clinical and Evidence Strategy program failure. 4. Biosimilar analytical similarity report cannot decide to drop a secondary yet after a boxed-warning proposal from the review division; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

ANALYSIS REQUIRED 1. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 2. Check whether biosimilar analytical similarity report supports the labeled claim 505(b)(2) development lead would keep. 3. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a boxed-warning proposal from the review division and write the one fact that would move to drop a secondary for 505(b)(2) development lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a mid-size sponsor after a complete response letter.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for 505(b)(2) development lead - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - What changes to drop a secondary if a boxed-warning proposal from the review division is later withdrawn - Named option among Proceed under protocol, Pause the pathway, Escalate safety review and the fact that kills the others